News & Topics

2011.09.27 PRODUCTNew Product: ReproCardio 2 (human iPSC-derived cardiomyocytes, frozen)

ReproCELL launches its second iPSC-cardiomyocyte product ReproCardio 2. Since the world’s first launch of the first version product (ReproCardio), ReproCELL has been continuously improving the products and now established frozen cells as a product. ReproCardio 2 contains natural population of human heart cells which are necessary for efficient prediction of compound effects in the drug development process. Please visit ReproCardio 2 product website to learn about it.

2011.04.18 PRODUCTNew product: Feeder-free medium ReproFF2

ReproCELL announces launch of a new product ReproFF2. ReproFF2 is a new feeder-free medium which doesn’t require everyday medium change while keeping the cells in a good condition without feeder cells. For more information please visit the product web page.

2011.01.05 ReproCELL to Enter Collaborative R&D on Human iPS Cell Derived Hepatocytes

ReproCELL announces today that it will start a collaboration with the National Institute of Biomedical Innovation (NIBIO) to develop human iPS cell-derived hepatocytes for in vitro drug screening, hepatic toxocity and drug metabolism. See the news

2010.09.01 ReproCELL announces new line of products in neuronal research using human iPS cells

Since April 2009, ReproCELL has been manufacturing iPS cell-derived cardiomyocytes for drug toxicity testing as the world’s first drug discovery support business provider founded on iPS cells. The prospective new offering of neuronal cells is the second line of products to be introduced by the company, and is a considerable expansion of their scope of business. ReproCELL will be the first in the world to offer iPS cell derived neuronal cells, and, more specifically, will provide dopaminergic neurons, motor neurons, and cerebral nerves.

2010.07.01 MEDIAReproCELL featured in Genetic Engineering & Biotechnology News

An article in Genetic Engineering & Biotechnology News, “Pharma’s R&D Focus Shifting to Stem Cells -Investors’ Interest in These Cells Increases as Scientists Continue to Unleash Their Potential” introduces ReproCELL’s new cardiotoxicity assay using iPSCs, QTempo, as well as its neural stem cell research. Read the article

2009.04.30 Cellartis and ReproCELL Sign Agreement to Provide CardioToxicity screening service using hESC derived Cardiomyocytes

Cellartis AB, a premier provider of stem cell derived products and technologies, and ReproCELL, a Japanese biotechnology company on the forefront of stem cell platforms and screening solutions, have today signed an agreement whereby ReproCELL can commercialise its QTempo Cardiotoxicity platform using beating human embryonic stem cell (hESC) derived Cardiomyocytes from Cellartis on a fee for service basis. In this first of a kind deal, cardiotoxicity testing via the ReproCELL QTempo platform will be commercially available using live and beating hESC derived cardiomyocytes to provide more accurate models of in vivo physiology. It is expected that the QTempo platform will emerge as the next generation solution to commercial hERG screening, […]

2009.04.16 New Stem Cell Technology to Improve Drug Safety

iPS cardiomyocytes used in a novel cardiotoxicity assay Drug side effects are a major problem for the drug industry. Even very rare events, when serious enough, can warrant drug withdrawal. Unfortunately, until a drug has been used by thousands of patients, these rare events can be impossible to predict. Identifying drugs that can trigger heart attacks before they reach the clinic is a major focus of ReproCELL. Current tests, especially at early stages of drug development, tend to focus on one aspect of heart cell function – the hERG ion channel. But there are a whole range of other ion channels, as well as other possible issues, which hERG tests […]

2008.11.05 PRODUCTReproFF launched

ReproCELL anounces the lanuch of ReproFF, a new product for human stem cell research. Many stem cells require feeder cells which form a layer beneath them, helping to optimize culture conditions. Subsequent analysis and applications for the stem cells may be impaired by the feeder cells. ReproFF was developed specifically to enable a wide range of primate (including human) stem cells to be grown in feeder free conditions. ReproFF offers seamless adaptation from feeder culture to feeder free with industry leading levels of cell vilability. ReproFF ia made to the same exacting standards as ReproCELL’s “Primate ES cell culture medium” which has beomce a gold standard in ES and iPS […]

2008.10.01 PRODUCTQTempo cardiotoxicity assay launched.

A major risk associated with new drugs is the occurrence of cardiotoxicity caused by off-target binding to heart cells. In addition to putting patients at risk, the financial consequences of drugs that cause such side effects can be significant. Over the last decade, assays focusing on the hERG protein have been developed. These hERG based assays manage to identify a majority of problem compounds before they reach the clinic. However, these tests still fail to detect many drugs that will cause adverse events in patients. QTempo is the world’s first commercially available assay that uses beating cardiomyocytes, hooked up to the lab equivalent of an ECG monitor, to accurately and […]